<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Med Biol Res</journal-id><journal-id journal-id-type="iso-abbrev">Braz. J. Med. Biol. Res</journal-id><journal-title-group><journal-title>Brazilian Journal of Medical and Biological Research</journal-title></journal-title-group><issn pub-type="ppub">0100-879X</issn><issn pub-type="epub">1414-431X</issn><publisher><publisher-name>Associa&#x000e7;&#x000e3;o Brasileira de Divulga&#x000e7;&#x000e3;o Cient&#x000ed;fica</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23532266</article-id><article-id pub-id-type="pmc">3854376</article-id><article-id pub-id-type="doi">10.1590/1414-431X20132774</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Investigation</subject></subj-group></article-categories><title-group><article-title>Association of <italic>MDR1</italic> gene polymorphisms
with the risk of hepatocellular carcinoma in the Chinese Han
population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gao</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><aff id="aff1">Tianjin Medical University, Tianjin, People's Republic of China</aff></contrib-group><author-notes><corresp>Correspondence: Jian Gao, Dafeng People's Hospital, No. 43 Health East,
Dafeng 224100, Jiangsu Province, People's Republic of China, E-mail: <email>jiangao_12@sina.com</email></corresp></author-notes><pub-date pub-type="epub"><day>15</day><month>3</month><year>2013</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2013</year></pub-date><volume>46</volume><issue>3</issue><fpage>311</fpage><lpage>317</lpage><history><date date-type="received"><day>29</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2013</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License, which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The multidrug resistance 1 gene (<italic>MDR1</italic>) is an important candidate
gene for influencing susceptibility to hepatocellular carcinoma (HCC). The
objective of the present study was to evaluate the association of
<italic>MDR1</italic> polymorphisms with the risk of HCC in the Chinese Han
population. A total of 353 HCC patients and 335 healthy subjects were enrolled
in the study. Polymerase chain reaction-restriction fragment length polymorphism
(PCR-RFLP), created restriction site-PCR (CRS-PCR) and DNA sequencing methods
were used to identify <italic>MDR1</italic> gene polymorphisms. Two allelic
variants (c.335T&#x0003e;C and c.3073A&#x0003e;C) were detected. The CC genotype of the
c.335T&#x0003e;C polymorphism was associated with an increased risk of developing HCC
compared to the TT genotype (OR = 2.161, 95%CI = 1.350-3.459, &#x003c7;<sup>2</sup> =
10.55, P = 0.0011). The risk of HCC was significantly higher for the CC genotype
in the c.3073A&#x0003e;C polymorphism compared to the AA genotype in the studied
populations (CC <italic>vs</italic> AA: OR = 2.575, 95%CI = 1.646-4.028,
&#x003c7;<sup>2</sup> = 17.64, P &#x0003c; 0.0001). The C allele of the c.335T&#x0003e;C and
c.3073A&#x0003e;C variants may contribute to the risk of HCC (C <italic>vs</italic> T
of c.335T&#x0003e;C: OR = 1.512, 95%CI = 1.208-1.893, &#x003c7;<sup>2</sup> = 13.07, P =
0.0003, and C <italic>vs</italic> A of c.3073A&#x0003e;C: OR = 1.646, 95%CI =
1.322-2.049, &#x003c7;<sup>2</sup> = 20.03, P &#x0003c; 0.0001). The c.335T&#x0003e;C and
c.3073A&#x0003e;C polymorphisms of the <italic>MDR1</italic> gene were associated
with the risk of occurrence of HCC in the Chinese Han population. Further
investigations are needed to confirm these results in larger different
populations.</p></abstract><kwd-group><kwd>Hepatocellular carcinoma</kwd><kwd>Multidrug resistance 1 gene</kwd><kwd>Single nucleotide polymorphisms</kwd><kwd>Susceptibility</kwd><kwd>Risk factors</kwd></kwd-group><counts><fig-count count="0"/><table-count count="4"/><ref-count count="35"/><page-count count="7"/></counts></article-meta></front><body><sec><title>Introduction</title><p>Hepatocellular carcinoma (HCC) is the fifth most common solid tumor and the third
leading cause of cancer-related deaths worldwide <xref ref-type="bibr" rid="B01">1</xref>-<xref ref-type="bibr" rid="B03">3</xref>. The estimated incidence of
new HCC cases is approximately 500,000&#x02013;1,000,000, causing 600,000 deaths globally
each year <xref ref-type="bibr" rid="B01">1</xref>. HCC shows significantly
geographic variation, with a very high incidence in China corresponding to
approximately 55% of annual new cases of HCC worldwide <xref ref-type="bibr" rid="B01">1</xref>,<xref ref-type="bibr" rid="B04">4</xref>. HCC has been one of
the most common causes of cancer-related deaths in China since the 1990s <xref ref-type="bibr" rid="B05">5</xref>,<xref ref-type="bibr" rid="B06">6</xref>.
Many environmental risk factors are associated with HCC, including chronic hepatitis
B (HBV) or hepatitis C viral infections, exposure to dietary aflatoxin B1, cigarette
smoking, alcohol consumption, diabetes mellitus, and conditions such as cirrhosis
<xref ref-type="bibr" rid="B07">7</xref>-<xref ref-type="bibr" rid="B10">10</xref>. Furthermore, it is generally accepted that genetic factors play
important roles in the pathogenesis of HCC <xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>. The exact mechanism of
hepatocarcinogenesis is still incompletely understood.</p><p>The human multidrug resistance 1 (<italic>MDR1</italic>) gene encodes a 170-kDa
transmembrane protein, P-glycoprotein (Pgp), which is a membrane protein acting as
an ATP-dependent exporter of xenobiotics from cells <xref ref-type="bibr" rid="B13">13</xref>. This MDR1 protein anchors to the cell membrane and acts as an efflux
transporter conferring resistance to a variety of natural cytotoxic drugs and
potentially toxic xenobiotics <xref ref-type="bibr" rid="B14">14</xref>-<xref ref-type="bibr" rid="B17">17</xref>. It has been reported that
<italic>MDR1</italic> is an important candidate gene influencing the risk for
HCC. Previous studies have mainly focused on the expression of <italic>MDR1</italic>
(often referred to as Pgp) in HCC cell lines and HCC specimens, with heterogeneous
and divergent results. It has been suggested that single nucleotide polymorphisms
(SNPs) in the <italic>MDR1</italic> gene may have an impact on the expression and
function of Pgp, therefore influencing susceptibility to various diseases, including
liver cancer <xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B25">25</xref>. <italic>MDR1</italic> is polymorphic, and at least 50 SNPs
have been reported <xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B30">30</xref>. Previous studies
have reported the association of <italic>MDR1</italic> gene polymorphisms with HCC
risk factors <xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>. However, the
association of the <italic>MDR1</italic> gene c.335T&#x0003e;C and c.3073A&#x0003e;C SNPs with
HCC has not been investigated. Thus, in the present study, we indentified these
genetic polymorphisms in the <italic>MDR1</italic> gene and evaluated their
association with the risk of liver cancer in the Chinese population.</p></sec><sec sec-type="methods"><title>Subjects and Methods</title><sec><title>Subjects</title><p>In this case-control study, 353 patients with HCC were enrolled from January 2008
to December 2011. HCC patients were diagnosed by doctors according to the
standards established by the Chinese Society of Liver Cancer (CSLC). The control
group consisted of 335 healthy subjects randomly selected from participants in
health screening programs to exclude those with a medical history of surgery,
cancer and other disease. All subjects were unrelated individuals of the Han
nationality. Information was obtained regarding demographic data as well as
related risk factors such as gender, age, smoking, drinking, hypertension,
diabetes mellitus, serum a-FP levels, family history of HCC, and HBV serological
markers [hepatitis-B surface antigen (HBs Ag), hepatitis-B surface antibody (HBs
Ab), hepatitis-Be antigen (HBe Ag), antibody to hepatitis-Be antigen (anti-HBe
Ab), and antibody to hepatitis-B core antigen (anti-HBc)] (<xref ref-type="table" rid="t01">Table 1</xref>). The current study was approved
by the local Institutional Ethics Committee, and all subjects gave written
informed consent to participate.</p><p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>Characteristics of the hepatocellular carcinoma (HCC) patients
and controls.</title></caption><graphic xlink:href="1414-431X-bjmbr-46-03-311-gt01"/><table-wrap-foot><fn id="TFN01t01"><p>Data are reported as number with percent in parentheses except
for mean &#x000b1; SD age. HBV = hepatitis B virus; HBs Ag = hepatitis B
surface antigen; a-FP = alpha-fetoprotein. Patients and controls
were compared by the chi-square (&#x003c7;<sup>2</sup>) test. There were
no statistically significant differences.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>Primer design and polymerase chain reaction (PCR) amplification</title><p>Genomic DNA was extracted from peripheral venous blood using the standard
phenol/chloroform extraction method. According to the DNA sequences (GenBank ID:
NG_011513.1) and mRNA sequences (GenBank ID: NM_000927.4) of the
<italic>MDR1</italic> gene, specific PCR primers were designed using the
Primer Premier 5.0 software (PREMIER Biosoft International, Canada). Primers,
annealing temperature, region, fragment sizes, and selected restriction enzymes
(MBI Fermentas, Germany) are shown in <xref ref-type="table" rid="t02">Table
2</xref>. PCR was carried out in a total volume of 20&#x02005;&#x000b5;L containing 50&#x02005;ng
template DNA, 1X buffer (100&#x02005;mM Tris-HCl, pH 8.3, 500&#x02005;mM KCl, 0.25&#x02005;&#x000b5;M primers,
2.0&#x02005;mM MgCl<sub>2</sub>, 0.25&#x02005;mM dNTPs, and 0.5&#x02005;U Taq DNA polymerase (Promega,
USA). The PCR protocol was 94&#x000b0;C for 5&#x02005;min, followed by 35 cycles at 94&#x000b0;C for
30&#x02005;s, annealing at the corresponding temperature (shown in <xref ref-type="table" rid="t02">Table 2</xref>) for 30&#x02005;s and 72&#x000b0;C for 30&#x02005;s, and a
final extension at 72&#x000b0;C for 8&#x02005;min. The PCR products were separated on 1.5%
agarose gel and photographed under UV light.</p><p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Table 2</label><caption><title>PCR, PCR-RFLP and CRS-PCR analysis used to genotype SNPs in the
<italic>MDR1</italic> gene.</title></caption><graphic xlink:href="1414-431X-bjmbr-46-03-311-gt02"/><table-wrap-foot><fn id="TFN01t02"><p>PCR = polymerase chain reaction; PCR-RFLP = PCR-restriction
fragment length polymorphism; CRS-PCR = created restriction site
PCR; SNPs = single nucleotide polymorphisms. Underlined
nucleotide indicates nucleotide mismatch enabling the use of the
selected restriction enzymes for discriminating sequence
variations.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>
<italic>MDR1</italic> genotyping</title><p>c.335T&#x0003e;C was investigated using the created restriction site-PCR (CRS-PCR)
method with one of the primers containing a nucleotide mismatch, which enables
the use of restriction enzymes for discriminating sequence variations <xref ref-type="bibr" rid="B33">33</xref>-<xref ref-type="bibr" rid="B35">35</xref>. c.3073A&#x0003e;C was detected by the
PCR-restriction fragment length polymorphism (PCR-RFLP) method. Following the
supplier's manual, 5-&#x000b5;L aliquots of PCR-amplified products were digested with 2
U restriction enzyme at 37&#x000b0;C for 10&#x02005;h. The digested products were separated by
2.5% agarose gel electrophoresis and observed directly under UV light in order
to determine the genotype of MDR1 polymorphisms. To confirm the genotype results
obtained by CRS-PCR and PCR-RFLP, about 20% of PCR-amplified products were
randomly selected for DNA sequencing (TaKaRa Biotechnology Co., Ltd.,
China).</p></sec><sec><title>Statistical analyses</title><p>All statistical analyses were performed using the Statistical Package for the
Social Sciences software (SPSS, Windows version release 15.0; SPSS Inc., USA).
The chi-square (&#x003c7;<sup>2</sup>) test was applied to evaluate Hardy&#x02013;Weinberg
equilibrium in all individuals, as well as allele and genotype frequencies, and
the general characteristics of the groups. Associations between
<italic>MDR1</italic> gene polymorphisms and HCC risk were estimated using
odds ratios (OR) and 95% confidence intervals (95%CI) for the comparison of
homozygotes (c.335T&#x0003e;C: CC <italic>vs</italic> TT, and c.3073A&#x0003e;C: CC
<italic>vs</italic> AA), and heterozygotes (c.335T&#x0003e;C: TC
<italic>vs</italic> TT, and c.3073A&#x0003e;C: AC <italic>vs</italic> AA),
dominant model (c.335T&#x0003e;C: CC+TC <italic>vs</italic> TT, and c.3073A&#x0003e;C:
CC+AC <italic>vs</italic> AA), recessive model (c.335T&#x0003e;C: CC
<italic>vs</italic> TC+TT, and c.3073A&#x0003e;C: CC <italic>vs</italic> AC+AA)
and allele contrast (c.335T&#x0003e;C: C <italic>vs</italic> T, and c.3073A&#x0003e;C: C
<italic>vs</italic> A). For all statistical tests, P &#x0003c; 0.05 was defined
as statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>General characteristics of the subjects</title><p>A total of 688 subjects were recruited for this study, including 353 HCC patients
and 335 controls. No significant differences between the patients and controls
in terms of gender and age distribution suggested that matching of subjects
based on these variables was adequate. Similarly, there were no significant
differences in smoking status or drinking consumption, hypertension or diabetes
mellitus between the patients and controls. The general characteristics of the
populations are summarized in <xref ref-type="table" rid="t01">Table
1</xref>.</p></sec><sec><title>Detection and genotyping of <italic>MDR1</italic> SNPs</title><p>In the present study, two allelic variants (c.335T&#x0003e;C and c.3073A&#x0003e;C) were
investigated by the CRS-PCR and PCR-RFLP methods, respectively. Sequence
analysis suggested that the c.335T&#x0003e;C polymorphism was caused by T to C
mutations in the 5&#x02032;-UTR of the human <italic>MDR1</italic> gene. As was the case
for the c.3073A&#x0003e;C variant, sequence analysis showed that this allelic variant
was caused by A to C mutations in exon 22 of the human <italic>MDR1</italic>
gene. Furthermore, this polymorphism caused a leucine (Leu) to phenylalanine
(Phe) amino acid replacement (p.Leu860Phe, Reference sequence GenBank IDs:
NG_011513.1, NM_000927.4 and NP_000918.2). The PCR product of c.335T&#x0003e;C was
digested with the <italic>Nla</italic>III enzyme and divided into three
genotypes: TT (208&#x02005;bp), TC (208, 185, and 23&#x02005;bp) and CC (185 and 23&#x02005;bp; <xref ref-type="table" rid="t02">Table 2</xref>). The PCR product of c.3073A&#x0003e;C
was digested with the <italic>Mae</italic>III enzyme and divided into three
genotypes: AA (163 and 86&#x02005;bp), AC (249, 163, and 86&#x02005;bp) and CC (249&#x02005;bp; <xref ref-type="table" rid="t02">Table 2</xref>).</p></sec><sec><title>Allelic and genotypic frequencies</title><p>The chi-square (&#x003c7;<sup>2</sup>) test for the c.335T&#x0003e;C and c.3073A&#x0003e;C variants
in the studied subjects suggested that the polymorphic sites were in
Hardy-Weinberg equilibrium (P &#x0003e; 0.05; <xref ref-type="table" rid="t03">Table
3</xref>). The allelic and genotypic frequencies of the c.335T&#x0003e;C and
c.3073A&#x0003e;C polymorphisms are presented in <xref ref-type="table" rid="t03">Table 3</xref>. Allele T and allele A were the predominant alleles in the
studied subjects in c.335T&#x0003e;C and c.3073A&#x0003e;C, respectively (<xref ref-type="table" rid="t03">Table 3</xref>). Regarding the c.335T&#x0003e;C
variant, the allelic frequencies of the patients (T = 61.19%; C = 38.81%) were
significantly different from those of controls (T = 70.45%; C = 29.55%;
&#x003c7;<sup>2</sup> = 13.0743; P = 0.0003). Furthermore, the genotypic frequencies
of the patients were not similar to those of the controls, with the differences
being statistically significant (&#x003c7;<sup>2</sup> = 11.8639; P = 0.0027; <xref ref-type="table" rid="t03">Table 3</xref>). Similarly, for the c.3073A&#x0003e;C
variant, the allelic frequencies of the patients (A = 55.24%; C = 44.76%) were
significantly different from those of the controls (A = 67.01%; C = 32.99%;
&#x003c7;<sup>2</sup> = 20.0272; P &#x0003c; 0.0001; <xref ref-type="table" rid="t03">Table 3</xref>). The genotypic frequencies of the patients were not similar
to those of the controls, with the differences being statistically significant
(&#x003c7;<sup>2</sup> = 18.4030; P = 0.0001; <xref ref-type="table" rid="t03">Table
3</xref>).</p><p>
<table-wrap id="t03" orientation="portrait" position="float"><label>Table 3</label><caption><title>Genotypic and allelic frequencies of c.335T&#x0003e;C and c.3073A&#x0003e;C
polymorphisms in the studied subjects.</title></caption><graphic xlink:href="1414-431X-bjmbr-46-03-311-gt03"/><table-wrap-foot><fn id="TFN01t03"><p>The chi-square (&#x003c7;<sup>2</sup>) test was used to evaluate
Hardy-Weinberg equilibrium in allele and genotype frequencies in
patients and controls.</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec><title>
<italic>MDR1</italic> polymorphisms and risk of HCC</title><p>Analysis of the association of genotypes/alleles from the c.335T&#x0003e;C and
c.3073A&#x0003e;C SNPs with the risk of HCC suggested that there was a significantly
increased risk of HCC (<xref ref-type="table" rid="t04">Table 4</xref>).
Regarding the c.335T&#x0003e;C SNPs, a significantly increased risk of liver cancer
was found in the homozygote comparison (CC <italic>vs</italic> TT: OR = 2.161,
95%CI = 1.350-3.459, &#x003c7;<sup>2</sup> = 10.55; P = 0.0011), heterozygote comparison
(TC <italic>vs</italic> TT: OR = 1.430, 95%CI = 1.034-1.977, &#x003c7;<sup>2</sup> =
4.68; P = 0.0310), dominant model (CC+TC <italic>vs</italic> TT: OR = 1.587,
95%CI = 1.173-2.146, &#x003c7;<sup>2</sup> = 9.01; P = 0.0027), recessive model (CC
<italic>vs</italic> TC+TT: OR = 1.826, 95%CI = 1.171-2.849, &#x003c7;<sup>2</sup> =
7.19; P = 0.0073), and allele contrast (C <italic>vs</italic> T: OR = 1.512,
95%CI = 1.208-1.893, &#x003c7;<sup>2</sup> = 13.07; P = 0.0003; <xref ref-type="table" rid="t04">Table 4</xref>). Similarly, there were significant differences in
the c.3073A&#x0003e;C SNPs for homozygote comparison (CC <italic>vs</italic> AA: OR =
2.575, 95%CI = 1.646-4.028, &#x003c7;<sup>2</sup> = 17.64; P &#x0003c; 0.0001), heterozygote
comparison (AC <italic>vs</italic> AA: OR = 1.519, 95%CI = 1.090-2.116,
&#x003c7;<sup>2</sup> = 6.13; P = 0.0130), dominant model (CC+AC <italic>vs</italic>
AA: OR = 1.759, 95%CI = 1.292-2.396, &#x003c7;<sup>2</sup> = 12.94; P = 0.0003),
recessive model (CC <italic>vs</italic> AC+AA: OR = 2.067, 95%CI = 1.370-3.120,
&#x003c7;<sup>2</sup> = 12.28; P = 0.0005), and allele contrast (C
<italic>vs</italic> A: OR = 1.646, 95%CI = 1.322-2.049, &#x003c7;<sup>2</sup> =
20.03; P &#x0003c; 0.0001; <xref ref-type="table" rid="t04">Table 4</xref>).</p><p>
<table-wrap id="t04" orientation="portrait" position="float"><label>Table 4</label><caption><title>Association between hepatocellular carcinoma risk and
<italic>MDR1</italic> SNPs.</title></caption><graphic xlink:href="1414-431X-bjmbr-46-03-311-gt04"/><table-wrap-foot><fn id="TFN01t04"><p>SNPs = single nucleotide polymorphisms. The association of
<italic>MDR1</italic> gene polymorphisms with hepatocellular
carcinoma risk was estimated using odds ratios (OR) and 95%
confidence intervals (95%CI) for the comparison of homozygotes,
heterozygotes, dominant model, recessive model, and allele
contrast by the chi-square (&#x003c7;<sup>2</sup>) test.</p></fn></table-wrap-foot></table-wrap>
</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>HCC is a common primary malignant tumor of the liver resulting from complex
interactions between environmental and genetic factors. Genotypic variation has a
key function in human phenotypic variability for cancer susceptibility. The present
study provided novel information on the effects of two novel allelic variants
(c.335T&#x0003e;C and c.3073A&#x0003e;C) of <italic>MDR1</italic> on susceptibility to HCC. We
observed a significant difference in allelic and genotypic frequencies between HCC
patients and healthy controls (<xref ref-type="table" rid="t03">Table 3</xref>).
Regarding the c.335T&#x0003e;C variants, the CC genotype was strongly associated with an
increased risk of developing HCC compared to TT and TC/TT genotypes. The risk of HCC
was significantly higher for the CC genotype in the c.3073A&#x0003e;C polymorphism
compared to the AA genotype and AC/AA carriers. Thus, the C allele of both
c.335T&#x0003e;C and c.3073A&#x0003e;C variants may contribute to the risk of HCC (C
<italic>vs</italic> T of c.335T&#x0003e;C: OR = 1.512, 95%CI = 1.208-1.893; P =
0.0003 and C <italic>vs</italic> A of c.3073A&#x0003e;C: OR = 1.646, 95%CI = 1.322-2.049;
P &#x0003c; 0.0001). The results of the present study suggest that the c.335T&#x0003e;C and
c.3073A&#x0003e;C polymorphisms of the <italic>MDR1</italic> gene are associated with the
risk of occurrence of HCC in the Chinese Han population. Several previous studies
have confirmed the relationship between <italic>MDR1</italic> polymorphisms and risk
factors for HCC <xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>. Wu et al. <xref ref-type="bibr" rid="B25">25</xref> analyzed the association between three
polymorphisms (C1236T, G2677A/T, C3435T) of the <italic>MDR1</italic> gene and the
risk of recurrence after liver transplantation. The association between
recurrence-free condition and being a 2677A carrier was significant (P = 0.019), but
no significant association was observed with other polymorphisms <xref ref-type="bibr" rid="B25">25</xref>. Wu et al. suggested that polymorphism of
the <italic>MDR1</italic> gene may be a valuable molecular marker for HCC recurrence
after liver transplantation. Chen et al. <xref ref-type="bibr" rid="B31">31</xref>
investigated the association between G2677T/A polymorphisms of the
<italic>MDR1</italic> gene and the risk of HCC <xref ref-type="bibr" rid="B31">31</xref> and suggested that 2677A may be an allele protecting against HCC,
while 2677T may be a risk gene for HCC <xref ref-type="bibr" rid="B31">31</xref>.
Chen et al. <xref ref-type="bibr" rid="B32">32</xref> detected a correlation of two
polymorphisms (C1236T and C3435T) of the <italic>MDR1</italic> gene with the
prognosis of HCC. The correlation between prognosis of HCC and the C3435T
polymorphism was significant (P = 0.037), but no significant correlation was
observed for the C1236T polymorphism (P = 0.762) <xref ref-type="bibr" rid="B32">32</xref>.</p><p>These findings suggested that the C3435T could be a positive candidate molecular
marker for the prognosis of HCC <xref ref-type="bibr" rid="B32">32</xref>. To the
best of our knowledge, this is the first report regarding the association of the
<italic>MDR1</italic> gene c.335T&#x0003e;C and c.3073A&#x0003e;C SNPs with the risk of
HCC. The findings could provide new evidence for further analysis of the importance
of the <italic>MDR1</italic> polymorphism for the risk of HCC. Larger prospective
studies will be needed to confirm these results in different populations.</p></sec></body><back><ref-list><title>References</title><ref id="B01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parkin</surname><given-names>DM</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Pisani</surname><given-names>P</given-names></name></person-group><article-title>Global cancer statistics, 2002</article-title><source>CA Cancer J Clin</source><year>2005</year><volume>55</volume><fpage>74</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.3322/canjclin.55.2.74</pub-id><pub-id pub-id-type="pmid">15761078</pub-id></element-citation></ref><ref id="B02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name><name><surname>Burroughs</surname><given-names>A</given-names></name><name><surname>Bruix</surname><given-names>J</given-names></name></person-group><article-title>Hepatocellular carcinoma</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1907</fpage><lpage>1917</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(03)14964-1</pub-id><pub-id pub-id-type="pmid">14667750</pub-id></element-citation></ref><ref id="B03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname><given-names>S</given-names></name><name><surname>Hyman</surname><given-names>D</given-names></name></person-group><article-title>Hepatocellular cancer: a guide for the
internist</article-title><source>Am J Med</source><year>2007</year><volume>120</volume><fpage>194</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2006.11.020</pub-id><pub-id pub-id-type="pmid">17349437</pub-id></element-citation></ref><ref id="B04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schutte</surname><given-names>K</given-names></name><name><surname>Bornschein</surname><given-names>J</given-names></name><name><surname>Malfertheiner</surname><given-names>P</given-names></name></person-group><article-title>Hepatocellular carcinoma - epidemiological trends
and risk factors</article-title><source>Dig Dis</source><year>2009</year><volume>27</volume><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">19546545</pub-id></element-citation></ref><ref id="B05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JG</given-names></name><name><surname>Zhang</surname><given-names>SW</given-names></name><name><surname>Chen</surname><given-names>WQ</given-names></name></person-group><article-title>[Analysis of liver cancer mortality in the national
retrospective sampling survey of death causes in China, 2</article-title><source>Zhonghua Yu Fang Yi Xue Za Zhi</source><year>2010</year><volume>44</volume><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">20654225</pub-id></element-citation></ref><ref id="B06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><article-title>DNA repair capacity, DNA-strand break repair gene
polymorphisms, and the incidence of hepatocellular carcinoma in southwestern
Guangxi of China</article-title><source>DNA Cell Biol</source><year>2012</year><volume>31</volume><fpage>1384</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1089/dna.2012.1646</pub-id><pub-id pub-id-type="pmid">22691054</pub-id></element-citation></ref><ref id="B07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farazi</surname><given-names>PA</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><article-title>Hepatocellular carcinoma pathogenesis: from genes
to environment</article-title><source>Nat Rev Cancer</source><year>2006</year><volume>6</volume><fpage>674</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1038/nrc1934</pub-id><pub-id pub-id-type="pmid">16929323</pub-id></element-citation></ref><ref id="B08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suriawinata</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>R</given-names></name></person-group><article-title>An update on the molecular genetics of
hepatocellular carcinoma</article-title><source>Semin Liver Dis</source><year>2004</year><volume>24</volume><fpage>77</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1055/s-2004-860865</pub-id><pub-id pub-id-type="pmid">15085488</pub-id></element-citation></ref><ref id="B09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname><given-names>FX</given-names></name><name><surname>Ribes</surname><given-names>J</given-names></name><name><surname>Diaz</surname><given-names>M</given-names></name><name><surname>Cleries</surname><given-names>R</given-names></name></person-group><article-title>Primary liver cancer: worldwide incidence and
trends</article-title><source>Gastroenterology</source><year>2004</year><volume>127</volume><fpage>S5</fpage><lpage>S16</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2004.09.011</pub-id><pub-id pub-id-type="pmid">15508102</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomaa</surname><given-names>AI</given-names></name><name><surname>Khan</surname><given-names>SA</given-names></name><name><surname>Toledano</surname><given-names>MB</given-names></name><name><surname>Waked</surname><given-names>I</given-names></name><name><surname>Taylor-Robinson</surname><given-names>SD</given-names></name></person-group><article-title>Hepatocellular carcinoma: epidemiology, risk
factors and pathogenesis</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>4300</fpage><lpage>4308</lpage><pub-id pub-id-type="doi">10.3748/wjg.14.4300</pub-id><pub-id pub-id-type="pmid">18666317</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nault</surname><given-names>JC</given-names></name><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name></person-group><article-title>Genetics of hepatobiliary
carcinogenesis</article-title><source>Semin Liver Dis</source><year>2011</year><volume>31</volume><fpage>173</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1055/s-0031-1276646</pub-id><pub-id pub-id-type="pmid">21538283</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorgeirsson</surname><given-names>SS</given-names></name><name><surname>Grisham</surname><given-names>JW</given-names></name></person-group><article-title>Molecular pathogenesis of human hepatocellular
carcinoma</article-title><source>Nat Genet</source><year>2002</year><volume>31</volume><fpage>339</fpage><lpage>346</lpage><pub-id pub-id-type="doi">10.1038/ng0802-339</pub-id><pub-id pub-id-type="pmid">12149612</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromm</surname><given-names>MF</given-names></name></person-group><article-title>Genetically determined differences in
P-glycoprotein function: implications for disease risk</article-title><source>Toxicology</source><year>2002</year><volume>181-182</volume><fpage>299</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/S0300-483X(02)00297-4</pub-id><pub-id pub-id-type="pmid">12505329</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gervasini</surname><given-names>G</given-names></name><name><surname>Carrillo Jose</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>San Jose</surname><given-names>C</given-names></name><name><surname>Cabanillas</surname><given-names>A</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name></person-group><article-title>Adenosine triphosphate-binding cassette B1 (ABCB1)
(multidrug resistance 1) G2677T/A gene polymorphism is associated with high
risk of lung cancer</article-title><source>Cancer</source><year>2006</year><volume>107</volume><fpage>2850</fpage><lpage>2857</lpage><pub-id pub-id-type="doi">10.1002/cncr.22332</pub-id><pub-id pub-id-type="pmid">17120199</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodor</surname><given-names>M</given-names></name><name><surname>Kelly</surname><given-names>EJ</given-names></name><name><surname>Ho</surname><given-names>RJ</given-names></name></person-group><article-title>Characterization of the human MDR1
gene</article-title><source>AAPS J</source><year>2005</year><volume>7</volume><fpage>E1</fpage><lpage>E5</lpage><pub-id pub-id-type="doi">10.1208/aapsj070101</pub-id><pub-id pub-id-type="pmid">16146331</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borst</surname><given-names>P</given-names></name><name><surname>Elferink</surname><given-names>RO</given-names></name></person-group><article-title>Mammalian ABC transporters in health and
disease</article-title><source>Annu Rev Biochem</source><year>2002</year><volume>71</volume><fpage>537</fpage><lpage>592</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.71.102301.093055</pub-id><pub-id pub-id-type="pmid">12045106</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambudkar</surname><given-names>SV</given-names></name><name><surname>Kimchi-Sarfaty</surname><given-names>C</given-names></name><name><surname>Sauna</surname><given-names>ZE</given-names></name><name><surname>Gottesman</surname><given-names>MM</given-names></name></person-group><article-title>P-glycoprotein: from genomics to
mechanism</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>7468</fpage><lpage>7485</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206948</pub-id><pub-id pub-id-type="pmid">14576852</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamroziak</surname><given-names>K</given-names></name><name><surname>Mlynarski</surname><given-names>W</given-names></name><name><surname>Balcerczak</surname><given-names>E</given-names></name><name><surname>Mistygacz</surname><given-names>M</given-names></name><name><surname>Trelinska</surname><given-names>J</given-names></name><name><surname>Mirowski</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional C3435T polymorphism of MDR1 gene: an
impact on genetic susceptibility and clinical outcome of childhood acute
lymphoblastic leukemia</article-title><source>Eur J Haematol</source><year>2004</year><volume>72</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0609.2004.00228.x</pub-id><pub-id pub-id-type="pmid">15059065</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonessa</surname><given-names>F</given-names></name><name><surname>Clarke</surname><given-names>R</given-names></name></person-group><article-title>ATP binding cassette transporters and drug
resistance in breast cancer</article-title><source>Endocr Relat Cancer</source><year>2003</year><volume>10</volume><fpage>43</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1677/erc.0.0100043</pub-id><pub-id pub-id-type="pmid">12653670</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurzawski</surname><given-names>M</given-names></name><name><surname>Drozdzik</surname><given-names>M</given-names></name><name><surname>Suchy</surname><given-names>J</given-names></name><name><surname>Kurzawski</surname><given-names>G</given-names></name><name><surname>Bialecka</surname><given-names>M</given-names></name><name><surname>Gornik</surname><given-names>W</given-names></name><etal/></person-group><article-title>Polymorphism in the P-glycoprotein drug transporter
MDR1 gene in colon cancer patients</article-title><source>Eur J Clin Pharmacol</source><year>2005</year><volume>61</volume><fpage>389</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1007/s00228-005-0926-5</pub-id><pub-id pub-id-type="pmid">15912392</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sohn</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>EJ</given-names></name><name><surname>Cha</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><etal/></person-group><article-title>MDR1 polymorphisms predict the response to
etoposide-cisplatin combination chemotherapy in small cell lung
cancer</article-title><source>Jpn J Clin Oncol</source><year>2006</year><volume>36</volume><fpage>137</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyi231</pub-id><pub-id pub-id-type="pmid">16478794</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Borght</surname><given-names>S</given-names></name><name><surname>Komuta</surname><given-names>M</given-names></name><name><surname>Libbrecht</surname><given-names>L</given-names></name><name><surname>Katoonizadeh</surname><given-names>A</given-names></name><name><surname>Aerts</surname><given-names>R</given-names></name><name><surname>Dymarkowski</surname><given-names>S</given-names></name><etal/></person-group><article-title>Expression of multidrug resistance-associated
protein 1 in hepatocellular carcinoma is associated with a more aggressive
tumour phenotype and may reflect a progenitor cell origin</article-title><source>Liver Int</source><year>2008</year><volume>28</volume><fpage>1370</fpage><lpage>1380</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2008.01889.x</pub-id><pub-id pub-id-type="pmid">19055643</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>S</given-names></name><name><surname>Mochida</surname><given-names>Y</given-names></name><name><surname>Uchiumi</surname><given-names>T</given-names></name><name><surname>Tahira</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Takagi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Genetic polymorphism at the 5&#x02032; regulatory region of
multidrug resistance 1 (<italic>MDR1</italic>) and its association with
interindividual variation of expression level in the colon</article-title><source>Mol Cancer Ther</source><year>2003</year><volume>2</volume><fpage>1351</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">14707276</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association of MDR1 gene SNPs and haplotypes with
the tacrolimus dose requirements in Han Chinese liver transplant
recipients</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e25933</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0025933</pub-id><pub-id pub-id-type="pmid">22110582</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>T</given-names></name><etal/></person-group><article-title>MDR1 gene polymorphisms and risk of recurrence in
patients with hepatocellular carcinoma after liver
transplantation</article-title><source>J Surg Oncol</source><year>2007</year><volume>96</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1002/jso.20774</pub-id><pub-id pub-id-type="pmid">17443726</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavaco</surname><given-names>I</given-names></name><name><surname>Gil</surname><given-names>JP</given-names></name><name><surname>Gil-Berglund</surname><given-names>E</given-names></name><name><surname>Ribeiro</surname><given-names>V</given-names></name></person-group><article-title>CYP3A4 and MDR1 alleles in a Portuguese
population</article-title><source>Clin Chem Lab Med</source><year>2003</year><volume>41</volume><fpage>1345</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">14580164</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chinn</surname><given-names>LW</given-names></name><name><surname>Kroetz</surname><given-names>DL</given-names></name></person-group><article-title>ABCB1 pharmacogenetics: progress, pitfalls, and
promise</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>81</volume><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100052</pub-id><pub-id pub-id-type="pmid">17259950</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmeyer</surname><given-names>S</given-names></name><name><surname>Burk</surname><given-names>O</given-names></name><name><surname>von Richter</surname><given-names>O</given-names></name><name><surname>Arnold</surname><given-names>HP</given-names></name><name><surname>Brockmoller</surname><given-names>J</given-names></name><name><surname>Johne</surname><given-names>A</given-names></name><etal/></person-group><article-title>Functional polymorphisms of the human
multidrug-resistance gene: multiple sequence variations and correlation of
one allele with P-glycoprotein expression and activity <italic>in
vivo</italic>
</article-title><source>Proc Natl Acad Sci U S A</source><year>2000</year><volume>97</volume><fpage>3473</fpage><lpage>3478</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.7.3473</pub-id><pub-id pub-id-type="pmid">10716719</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaya</surname><given-names>P</given-names></name><name><surname>Gunduz</surname><given-names>U</given-names></name><name><surname>Arpaci</surname><given-names>F</given-names></name><name><surname>Ural</surname><given-names>AU</given-names></name><name><surname>Guran</surname><given-names>S</given-names></name></person-group><article-title>Identification of polymorphisms on the MDR1 gene
among Turkish population and their effects on multidrug resistance in acute
leukemia patients</article-title><source>Am J Hematol</source><year>2005</year><volume>80</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1002/ajh.20427</pub-id><pub-id pub-id-type="pmid">16138358</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pechandova</surname><given-names>K</given-names></name><name><surname>Buzkova</surname><given-names>H</given-names></name><name><surname>Slanar</surname><given-names>O</given-names></name><name><surname>Perlik</surname><given-names>F</given-names></name></person-group><article-title>Polymorphisms of the MDR1 gene in the Czech
population</article-title><source>Folia Biol</source><year>2006</year><volume>52</volume><fpage>184</fpage><lpage>189</lpage></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YD</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Feng</surname><given-names>ST</given-names></name><name><surname>Zhang</surname><given-names>YX</given-names></name></person-group><article-title>A case-control study on the association between
genetic polymorphisms of MDR1 and hepatic cell cancer
susceptibility</article-title><source>Chin Clin Oncol</source><year>2009</year><volume>14</volume><fpage>1077</fpage><lpage>1081</lpage></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>XJ</given-names></name><name><surname>Wang</surname><given-names>XG</given-names></name><name><surname>Shen</surname><given-names>YJ</given-names></name><name><surname>Zhou</surname><given-names>HK</given-names></name><name><surname>Ni</surname><given-names>QF</given-names></name><name><surname>Fei</surname><given-names>JG</given-names></name><etal/></person-group><article-title>Correlation of MDR1 single nucleotide polymorphism
with prognosis of hepatocellular carcinoma</article-title><source>J Chin Oncol</source><year>2011</year><volume>17</volume><fpage>209</fpage><lpage>211</lpage></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>ZR</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Investigation on BRCA1 SNPs and its effects on
mastitis in Chinese commercial cattle</article-title><source>Gene</source><year>2012</year><volume>505</volume><fpage>190</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1016/j.gene.2012.05.010</pub-id><pub-id pub-id-type="pmid">22583824</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>ZR</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>SZ</given-names></name></person-group><article-title>SNPs identification and its correlation analysis
with milk somatic cell score in bovine MBL1 gene</article-title><source>Mol Biol Rep</source><year>2013</year><volume>40</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-1934-z</pub-id><pub-id pub-id-type="pmid">23114911</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>ZR</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>HJ</given-names></name><name><surname>Xu</surname><given-names>SZ</given-names></name></person-group><article-title>Effects of DGAT1 gene on meat and carcass fatness
quality in Chinese commercial cattle</article-title><source>Mol Biol Rep</source><year>2013</year><volume>40</volume><fpage>1947</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.1007/s11033-012-2251-2</pub-id><pub-id pub-id-type="pmid">23143182</pub-id></element-citation></ref></ref-list></back></article>